Eyad Abdulrazzak, Butros Fakhoury, Ali Jaan, Mohamed Ebrahim, Imad Alabdul Razzak, Ahmed Shehadah, Leandro Sierra, Hazem Abosheaishaa, Elliot B. Tapper, Hirsh D. Trivedi
{"title":"他汀类药物治疗和肝硬化门静脉压降低：系统回顾和荟萃分析","authors":"Eyad Abdulrazzak, Butros Fakhoury, Ali Jaan, Mohamed Ebrahim, Imad Alabdul Razzak, Ahmed Shehadah, Leandro Sierra, Hazem Abosheaishaa, Elliot B. Tapper, Hirsh D. Trivedi","doi":"10.1111/liv.70326","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Aims</h3>\n \n <p>Portal hypertension is the principal driver of cirrhosis decompensation, leading to heightened morbidity and mortality. While non-selective beta-blockers (NSBBs) remain the standard of care, up to 45% of patients fail to achieve sufficient portal pressure reduction. Statins have gained attention as a potential therapeutic agent for portal hypertension. We conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) to evaluate the impact of statins on portal pressure and cirrhosis-related outcomes.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We searched five databases through November 2024 for RCTs evaluating statin therapy in adults with cirrhosis and clinically significant portal hypertension (CSPH). The primary outcome was HVPG reduction, assessed as an absolute decrease or the proportion achieving a haemodynamic response (HVPG reduction ≥ 20% from baseline or to ≤ 12 mmHg). Secondary outcomes included variceal bleeding, ascites and mortality. Random-effects meta-analyses were performed using pooled mean differences (MDs) and risk differences (RDs) with 95% confidence intervals (CIs).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Six RCTs (<i>n</i> = 492) were included. Statin therapy was associated with significant HVPG reduction (MD: 1.1 mmHg; 95% CI: 0.44–1.77; <i>I</i><sup>2</sup> = 38.7%) and higher hemodynamic response (RD: 0.24; 95% CI: 0.02–0.45; <i>I</i><sup>2</sup> = 76.8%). No significant differences were seen in variceal bleeding, ascites or mortality. On subgroup analysis, HVPG benefit was limited to studies with short-term follow-up. In studies comparing statin plus NSBB to NSBB alone, the addition of statins further reduced HVPG.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Statins modestly lower HVPG in cirrhosis-related portal hypertension and may be a useful adjunct to NSBBs. Larger trials are needed to assess long-term clinical benefits.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>PROSPERO registration number: CRD42025622478</p>\n </section>\n </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 10","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Statin Therapy and Portal Pressure Reduction in Cirrhosis: A Systematic Review and Meta-Analysis\",\"authors\":\"Eyad Abdulrazzak, Butros Fakhoury, Ali Jaan, Mohamed Ebrahim, Imad Alabdul Razzak, Ahmed Shehadah, Leandro Sierra, Hazem Abosheaishaa, Elliot B. Tapper, Hirsh D. Trivedi\",\"doi\":\"10.1111/liv.70326\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background and Aims</h3>\\n \\n <p>Portal hypertension is the principal driver of cirrhosis decompensation, leading to heightened morbidity and mortality. While non-selective beta-blockers (NSBBs) remain the standard of care, up to 45% of patients fail to achieve sufficient portal pressure reduction. Statins have gained attention as a potential therapeutic agent for portal hypertension. We conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) to evaluate the impact of statins on portal pressure and cirrhosis-related outcomes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We searched five databases through November 2024 for RCTs evaluating statin therapy in adults with cirrhosis and clinically significant portal hypertension (CSPH). The primary outcome was HVPG reduction, assessed as an absolute decrease or the proportion achieving a haemodynamic response (HVPG reduction ≥ 20% from baseline or to ≤ 12 mmHg). Secondary outcomes included variceal bleeding, ascites and mortality. Random-effects meta-analyses were performed using pooled mean differences (MDs) and risk differences (RDs) with 95% confidence intervals (CIs).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Six RCTs (<i>n</i> = 492) were included. Statin therapy was associated with significant HVPG reduction (MD: 1.1 mmHg; 95% CI: 0.44–1.77; <i>I</i><sup>2</sup> = 38.7%) and higher hemodynamic response (RD: 0.24; 95% CI: 0.02–0.45; <i>I</i><sup>2</sup> = 76.8%). No significant differences were seen in variceal bleeding, ascites or mortality. On subgroup analysis, HVPG benefit was limited to studies with short-term follow-up. In studies comparing statin plus NSBB to NSBB alone, the addition of statins further reduced HVPG.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Statins modestly lower HVPG in cirrhosis-related portal hypertension and may be a useful adjunct to NSBBs. Larger trials are needed to assess long-term clinical benefits.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial Registration</h3>\\n \\n <p>PROSPERO registration number: CRD42025622478</p>\\n </section>\\n </div>\",\"PeriodicalId\":18101,\"journal\":{\"name\":\"Liver International\",\"volume\":\"45 10\",\"pages\":\"\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2025-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Liver International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/liv.70326\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/liv.70326","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Statin Therapy and Portal Pressure Reduction in Cirrhosis: A Systematic Review and Meta-Analysis
Background and Aims
Portal hypertension is the principal driver of cirrhosis decompensation, leading to heightened morbidity and mortality. While non-selective beta-blockers (NSBBs) remain the standard of care, up to 45% of patients fail to achieve sufficient portal pressure reduction. Statins have gained attention as a potential therapeutic agent for portal hypertension. We conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) to evaluate the impact of statins on portal pressure and cirrhosis-related outcomes.
Methods
We searched five databases through November 2024 for RCTs evaluating statin therapy in adults with cirrhosis and clinically significant portal hypertension (CSPH). The primary outcome was HVPG reduction, assessed as an absolute decrease or the proportion achieving a haemodynamic response (HVPG reduction ≥ 20% from baseline or to ≤ 12 mmHg). Secondary outcomes included variceal bleeding, ascites and mortality. Random-effects meta-analyses were performed using pooled mean differences (MDs) and risk differences (RDs) with 95% confidence intervals (CIs).
Results
Six RCTs (n = 492) were included. Statin therapy was associated with significant HVPG reduction (MD: 1.1 mmHg; 95% CI: 0.44–1.77; I2 = 38.7%) and higher hemodynamic response (RD: 0.24; 95% CI: 0.02–0.45; I2 = 76.8%). No significant differences were seen in variceal bleeding, ascites or mortality. On subgroup analysis, HVPG benefit was limited to studies with short-term follow-up. In studies comparing statin plus NSBB to NSBB alone, the addition of statins further reduced HVPG.
Conclusions
Statins modestly lower HVPG in cirrhosis-related portal hypertension and may be a useful adjunct to NSBBs. Larger trials are needed to assess long-term clinical benefits.
期刊介绍：
Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
